• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ituran Location and Control Posts Q3 Results, Joins Crown Castle, Shopify And Other Big Stocks Moving Higher On Monday

    11/27/23 10:17:21 AM ET
    $AAOI
    $AFRM
    $CAAP
    $CCI
    Semiconductors
    Technology
    Finance: Consumer Services
    Finance
    Get the next $AAOI alert in real time by email

    U.S. stocks traded mostly lower, with the Dow Jones falling around 50 points on Monday.

    Shares of Ituran Location and Control Ltd. (NASDAQ:ITRN) gained during Monday’s session after the company reported third-quarter financial results.

    The company posted quarterly earnings of 63 cents per share, up from 49 cents per share in the year-ago period. The company’s quarterly sales rose 12% to $81.05 million.

    Ituran Location and Control shares gained 11.3% to $27.69 on Monday.

    Here are some other big stocks recording gains in today’s session.

    • Affirm Holdings, Inc. (NASDAQ:AFRM) surged 13.7% to $29.82 following reports of record 'buy now, pay later' predictions on Cyber Monday.
    • IRSA Inversiones y Representaciones Sociedad Anónima (NYSE:IRS) shares jumped 12.4% to $9.13.
    • EHang Holdings Limited (NASDAQ:EH) rose 12.1% to $19.71.
    • Xenon Pharmaceuticals Inc. (NASDAQ:XENE) surged 10.2% to $31.93 after the company announced topline results from the Phase 2 proof-of-concept X-NOVA clinical trial of XEN1101 in MDD.
    • Applied Optoelectronics, Inc. (NASDAQ:AAOI) climbed 8.8% to $14.19.
    • Corporación América Airports S.A. (NYSE:CAAP) rose 8.1% to $14.56.
    • Global-e Online Ltd. (NASDAQ:GLBE) climbed 7.4% to $33.95.
    • Telecom Argentina S.A. (NYSE:TEO) gained 6.7% to $8.26.
    • Grupo Financiero Galicia S.A. (NASDAQ:GGAL) rose 6.7% to $16.35.
    • DRDGOLD Limited (NYSE:DRD) gained 5.8% to $9.19.
    • Roku, Inc. (NASDAQ:ROKU) rose 5.8% to $100.51.
    • Crown Castle Inc. (NYSE:CCI) rose 4.7% to $108.46 after activist fund Elliott took a $2 billion stake in the company and suggested operational improvements.
    • Teva Pharmaceutical Industries Limited (NYSE:TEVA) gained 4.1% to $9.94 after UBS upgraded the stock from Neutral to Buy and raised its price target from $11 to $13.
    • Shopify Inc. (NYSE:SHOP) gained 4% to $73.20 after the company announced that Shopify merchants set a Black Friday record with a combined $4.1 billion in sales.

     

    Now Read This: Goldman Sachs, VeriSign And 2 Other Stocks Insiders Are Selling

    Get the next $AAOI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AAOI
    $AFRM
    $CAAP
    $CCI

    CompanyDatePrice TargetRatingAnalyst
    Crown Castle Inc.
    $CCI
    3/5/2026$102.00Outperform
    Bernstein
    Affirm Holdings Inc.
    $AFRM
    3/5/2026$82.00Buy
    BofA Securities
    Applied Optoelectronics Inc.
    $AAOI
    2/27/2026$55.00Outperform → Market Perform
    Northland Capital
    Applied Optoelectronics Inc.
    $AAOI
    2/27/2026$54.00Sell → Neutral
    B. Riley Securities
    Xenon Pharmaceuticals Inc.
    $XENE
    2/24/2026$60.00Outperform
    Wolfe Research
    Affirm Holdings Inc.
    $AFRM
    2/20/2026$55.00Neutral
    Robert W. Baird
    Shopify Inc.
    $SHOP
    2/17/2026$150.00Hold → Buy
    Truist
    Roku Inc.
    $ROKU
    2/13/2026$118.00Neutral → Buy
    Rosenblatt
    More analyst ratings

    $AAOI
    $AFRM
    $CAAP
    $CCI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Legal Officer Mcavoy David R. bought $20,988 worth of Ordinary Shares (1,113 units at $18.86), increasing direct ownership by 9% to 13,027 units (SEC Form 4)

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    9/9/25 4:02:56 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Lin Chih-Hsiang (Thompson) bought $174,057 worth of shares (8,075 units at $21.56), increasing direct ownership by 0.14% to 1,663,490 units (SEC Form 4)

    4 - APPLIED OPTOELECTRONICS, INC. (0001158114) (Issuer)

    8/15/25 4:19:44 PM ET
    $AAOI
    Semiconductors
    Technology

    Director Lin Che-Wei bought $99,739 worth of shares (4,609 units at $21.64), increasing direct ownership by 2% to 253,506 units (SEC Form 4)

    4 - APPLIED OPTOELECTRONICS, INC. (0001158114) (Issuer)

    8/15/25 4:19:30 PM ET
    $AAOI
    Semiconductors
    Technology

    $AAOI
    $AFRM
    $CAAP
    $CCI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Xenon Pharmaceuticals Announces Proposed Public Offering

    VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that it has commenced an underwritten public offering of $500.0 million of its common shares, pursuant to its existing shelf registration statement. All of the common shares in this offering are being offered by Xenon. In addition, Xenon intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $75.0 million of common shares at the public offer

    3/9/26 4:01:00 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)

    X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg dose compared with -10.4% for placebo (p=0.000000000006)X-TOLE2 outperformed Phase 2b X-TOLE study, with a placebo-adjusted MPC of -42.7% in 25 mg group in X-TOLE2 compared to -34.6% in 25 mg group in X-TOLEAzetukalner was generally well-tolerated with a safety profile consistent with X-TOLE studyXenon anticipates submitting New Drug Application for azetukalner in FOS to the U.S. FDA in Q3 2026X-TOLE2 data to be featured in Late Breaking Science oral presentation at AAN Annual Meeting in AprilCompany to host conference call and webcast today at 8:00

    3/9/26 7:00:00 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AOI Receives First Volume Order of 1.6T Data Center Transceivers from Major Hyperscale Customer

    SUGAR LAND, Texas, March 09, 2026 (GLOBE NEWSWIRE) -- Applied Optoelectronics Inc. (NASDAQ:AAOI), a leading provider of advanced optical and HFC networking products that power AI, today announced it received its first volume order for its 1.6T data center transceivers from one of its long-term major hyperscale customers to boost its network bandwidth for AI workloads. "We are seeing a clear progression toward higher-speed optics as AI clusters scale, and our transceiver portfolio enables our customers to order both 400G and 800G or 1.6T from us," said Dr. Thompson Lin, Founder, Chairman, and CEO of AOI. "With expansion at our Taiwan facility ongoing and construction underway at our new f

    3/9/26 7:00:00 AM ET
    $AAOI
    Semiconductors
    Technology

    $AAOI
    $AFRM
    $CAAP
    $CCI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bernstein initiated coverage on Crown Castle with a new price target

    Bernstein initiated coverage of Crown Castle with a rating of Outperform and set a new price target of $102.00

    3/5/26 8:32:16 AM ET
    $CCI
    Real Estate Investment Trusts
    Real Estate

    BofA Securities resumed coverage on Affirm with a new price target

    BofA Securities resumed coverage of Affirm with a rating of Buy and set a new price target of $82.00

    3/5/26 8:29:12 AM ET
    $AFRM
    Finance: Consumer Services
    Finance

    Applied Optoelectronics downgraded by Northland Capital with a new price target

    Northland Capital downgraded Applied Optoelectronics from Outperform to Market Perform and set a new price target of $55.00

    2/27/26 8:26:41 AM ET
    $AAOI
    Semiconductors
    Technology

    $AAOI
    $AFRM
    $CAAP
    $CCI
    SEC Filings

    View All

    SEC Form 6-K filed by Telecom Argentina SA

    6-K - TELECOM ARGENTINA SA (0000932470) (Filer)

    3/10/26 3:32:01 PM ET
    $TEO
    Telecommunications Equipment
    Telecommunications

    SEC Form 6-K filed by Telecom Argentina SA

    6-K - TELECOM ARGENTINA SA (0000932470) (Filer)

    3/10/26 3:30:34 PM ET
    $TEO
    Telecommunications Equipment
    Telecommunications

    SEC Form 6-K filed by Telecom Argentina SA

    6-K - TELECOM ARGENTINA SA (0000932470) (Filer)

    3/10/26 3:27:18 PM ET
    $TEO
    Telecommunications Equipment
    Telecommunications

    $AAOI
    $AFRM
    $CAAP
    $CCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Applied Optoelectronics Inc.

    4 - APPLIED OPTOELECTRONICS, INC. (0001158114) (Issuer)

    3/10/26 5:23:43 PM ET
    $AAOI
    Semiconductors
    Technology

    SEC Form 4 filed by Applied Optoelectronics Inc.

    4 - APPLIED OPTOELECTRONICS, INC. (0001158114) (Issuer)

    3/10/26 4:43:52 PM ET
    $AAOI
    Semiconductors
    Technology

    Chief Financial Officer Murry Stefan J. sold $451,044 worth of shares (4,000 units at $112.76), decreasing direct ownership by 1% to 280,070 units (SEC Form 4)

    4 - APPLIED OPTOELECTRONICS, INC. (0001158114) (Issuer)

    3/10/26 4:43:11 PM ET
    $AAOI
    Semiconductors
    Technology

    $AAOI
    $AFRM
    $CAAP
    $CCI
    Financials

    Live finance-specific insights

    View All

    Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)

    X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg dose compared with -10.4% for placebo (p=0.000000000006)X-TOLE2 outperformed Phase 2b X-TOLE study, with a placebo-adjusted MPC of -42.7% in 25 mg group in X-TOLE2 compared to -34.6% in 25 mg group in X-TOLEAzetukalner was generally well-tolerated with a safety profile consistent with X-TOLE studyXenon anticipates submitting New Drug Application for azetukalner in FOS to the U.S. FDA in Q3 2026X-TOLE2 data to be featured in Late Breaking Science oral presentation at AAN Annual Meeting in AprilCompany to host conference call and webcast today at 8:00

    3/9/26 7:00:00 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

    VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, will announce topline data from the Phase 3 X-TOLE2 study of azetukalner, a novel, potent KV7 potassium channel opener, in patients with focal onset seizures (FOS), on Monday, March 9, 2026. Conference Call/Webcast Information:  Date:Monday, March 9, 2026  Time:8:00 am ET (5:00 am PT)  Webcast:Pre-register here  Dial-In:(800) 715-9871 toll-free or (646) 307-1963 for international callers  Conference ID:78

    3/8/26 2:00:00 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ITURAN LOCATION AND CONTROL LTD Announces Dividend Distribution of $30 Million for the Fourth Quarter of 2025

    AZOUR, Israel, March 5, 2026 /PRNewswire/ -- Ituran Location and Control Ltd. (NASDAQ:ITRN) announced that the Board of Directors approved the distribution of a cash dividend in the amount of $1.50 per share, totaling approximately US$ 30 million. The dividend will be paid to shareholders of record as of March 30, 2026. The Company will pay the dividend out on April 16, 2026, net of taxes at the rate of 20% (a lower rate than standard) as the dividend is distributed from "Preferred Income" and/or "Preferred Technological Income", as defined under the Encouragement of Capital Investment Law and the provisions of a tax ruling (the "Ruling") received from the Israel Tax Authority (the "ITA") wi

    3/5/26 7:30:00 AM ET
    $ITRN
    Electronic Components
    Technology

    $AAOI
    $AFRM
    $CAAP
    $CCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Grupo Financiero Galicia S.A.

    SC 13G - GRUPO FINANCIERO GALICIA SA (0001114700) (Subject)

    12/10/24 5:21:23 PM ET
    $GGAL
    Commercial Banks
    Finance

    SEC Form SC 13D filed by DRDGOLD Limited

    SC 13D - DRDGOLD LTD (0001023512) (Subject)

    11/14/24 5:21:04 PM ET
    $DRD
    Precious Metals
    Basic Materials

    Amendment: SEC Form SC 13G/A filed by Global-E Online Ltd.

    SC 13G/A - Global-E Online Ltd. (0001835963) (Subject)

    11/14/24 4:48:05 PM ET
    $GLBE
    Computer Software: Prepackaged Software
    Technology

    $AAOI
    $AFRM
    $CAAP
    $CCI
    Leadership Updates

    Live Leadership Updates

    View All

    EHang Appoints Mr. Shuai Feng as Chief Technology Officer to Deepen Technological Innovation and Industrial Synergy, Empowering Commercialization

    GUANGZHOU, China, Jan. 16, 2026 (GLOBE NEWSWIRE) -- EHang Holdings Limited (NASDAQ:EH) ("EHang" or the "Company"), a global leader in advanced air mobility ("AAM") technology, today officially announced that the Board of Directors of the Company (the "Board") has approved and appointed Mr. Shuai Feng as the Chief Technology Officer ("CTO"), effective on January 14, 2026. This appointment represents a key milestone in the Company's technology strategy. Building on the solid foundation established through years of direct leadership over technology development by the Company's Founder, Chairman, and Chief Executive Officer Mr. Huazhi Hu, EHang is advancing its technology management framework

    1/16/26 8:00:48 AM ET
    $EH
    Aerospace
    Industrials

    Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma's Biggest Challenges

    First cohort features 7 real-world challenges across R&D, manufacturing and supply chain, commercial and medical affairs Teva's first-ever global innovation platform aims to accelerate patient impact and drive business transformation, as part of its Pivot to Growth StrategyRise will enable startups and tech players worldwide to validate their solutions in real-world settings, scaling impact across Teva's global ecosystem including in the U.S., Europe, Israel and beyond TEL AVIV, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today unveiled Teva Rise, a global open innovation platform designed to harness the power of a variety of disruptive tech

    11/19/25 8:00:00 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer

    VANCOUVER, British Columbia and BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced the appointment of Tucker Kelly as Chief Financial Officer (CFO) and member of the Xenon senior executive team. Mr. Kelly is a proven executive who brings extensive strategic and commercial finance expertise, both in the U.S. and internationally, that will help the Company prepare for the anticipated commercialization of its lead candidate, azetukalner. Azetukalner is currently being studi

    10/16/25 8:30:00 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care